Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104093 | 1.00 | HRH3 (0.51) | HRH3PDK1CCR2KCNH2CHRM2 | |
| SCHEMBL16000544 | 1.00 | HRH3 (0.51) | HRH3PDK1CCR2KCNH2CHRM2 | |
| SCHEMBL26999673 | 0.89 | PDK1 (0.50) | HRH3PDK1CCR2KCNH2ERBB2 | |
| SCHEMBL26789735 | 0.85 | HRH3 (0.44) | HRH3PDK1CCR2KCNH2CHRM2 | |
| SCHEMBL23467615 | 0.85 | PDK1 (0.45) | HRH3PDK1CCR2KCNH2ADORA2A | |
| SCHEMBL16812143 | 0.85 | HRH3 (0.49) | HRH3PDK1CCR2KCNH2CHRM2 | |
| SCHEMBL20624866 | 0.85 | PDK1 (0.45) | HRH3PDK1CCR2KCNH2ADORA2A | |
| SCHEMBL25081867 | 0.83 | HRH3 (0.40) | HRH3PDK1CCR2KCNH2 | |
| SCHEMBL16000539 | 0.82 | HRH3 (0.53) | HRH3PDK1CCR2KCNH2CHRM2 | |
| SCHEMBL12122183 | 0.82 | HRH3 (0.53) | HRH3PDK1CCR2KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
| US-20210196724-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | ATHENEX, INC. | 2021-07-01 | — | — | US | disclosed |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | Nimbus Saturn, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| WO-2021072238-A1 | FEEDER-BASED AND FEEDER-FREE STEM CELL CULTURE SYSTEMS FOR STRATIFIED EPITHELIAL STEM CELLS, AND USES RELATED THERETO | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-04-15 | — | — | WO | disclosed |
| US-10000475-B2 | Triazine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170298027-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2017-10-19 | — | — | US | disclosed |
| WO-2017106564-A1 | COMBINATION OF A JAK INHIBITOR AND A SYK INHIBITOR FOR TREATING CANCERS AND INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170173034-A1 | COMBINATION OF A JAK INHIBITOR AND A SYK INHIBITOR FOR TREATING CANCERS AND INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170173034-A1 | COMBINATION OF A JAK INHIBITOR AND A SYK INHIBITOR FOR TREATING CANCERS AND INFLAMMATORY DISORDERS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9340538-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-05-17 | — | — | US | disclosed |
| US-20150353512-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-12-10 | — | — | US | disclosed |
| US-9120786-B2 | Triazine carboxamides as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
| US-20140249128-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | HRH3 1555/4885PDK1 601/4885CCR2 3894/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | HRH3 2176/4885PDK1 1301/4885CCR2 1554/4885 |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HRH3 387/4885PDK1 185/4885CCR2 4148/4885 |
| US-20140249128-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, SCN2A, SCN2B | HRH3 1032/4885PDK1 4248/4885CCR2 2509/4885 |
| US-11028085-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists | HIPK1, PDXK, IP6K1 | HRH3 303/4885PDK1 327/4885CCR2 2119/4885 |
| US-20150353512-A1 | TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, SCN2A, SCN2B | HRH3 1032/4885PDK1 4248/4885CCR2 2509/4885 |
| US-20170298027-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX3, CACNA1A, P2RX4 | HRH3 1328/4885PDK1 2687/4885CCR2 2648/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | HRH3 387/4885PDK1 185/4885CCR2 4148/4885 |
| US-10000475-B2 | Triazine carboxamides as sodium channel blockers | TRPV1, SCN2A, SCN2B | HRH3 1032/4885PDK1 4248/4885CCR2 2509/4885 |
| US-20170173034-A1 | COMBINATION OF A JAK INHIBITOR AND A SYK INHIBITOR FOR TREATING CANCERS AND INFLAMMATORY DISORDERS | SYK, BTK, JAK1 | HRH3 3206/4885PDK1 3064/4885CCR2 1309/4885 |
| US-11021481-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, PDXK, IP6K1 | HRH3 303/4885PDK1 327/4885CCR2 2119/4885 |
| US-20210196724-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | PLK1, MAP3K2, TNK2 | HRH3 3066/4885PDK1 231/4885CCR2 2000/4885 |
| US-11034694-B2 | Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists | HIPK1, IP6K1, PDXK | HRH3 288/4885PDK1 163/4885CCR2 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.